Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Age-specific population attributable risk factors for all-cause and cause-specific mortality in type 2 diabetes: An analysis of a 6-year prospective cohort study of over 360,000 people in Hong Kong.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science, [2004]-
    • الموضوع:
    • نبذة مختصرة :
      Background: The prevalence of type 2 diabetes has increased in both young and old people. We examined age-specific associations and population attributable fractions (PAFs) of risk factors for all-cause and cause-specific mortality in people with type 2 diabetes.
      Methods and Findings: We analysed data from 360,202 Chinese with type 2 diabetes who participated in a territory-wide diabetes complication screening programme in Hong Kong between January 2000 and December 2019. We compared the hazard ratios and PAFs of eight risk factors, including three major comorbidities (cardiovascular disease [CVD], chronic kidney disease [CKD], all-site cancer) and five modifiable risk factors (suboptimal HbA1c, suboptimal blood pressure, suboptimal low-density lipoprotein cholesterol, smoking, and suboptimal weight), for mortality across four age groups (18 to 54, 55 to 64, 65 to 74, and ≥75 years). During a median 6.0 years of follow-up, 44,396 people died, with cancer, CVD, and pneumonia being the leading causes of death. Despite a higher absolute mortality risk in older people (crude all-cause mortality rate: 59.7 versus 596.2 per 10,000 person-years in people aged 18 to 54 years versus those aged ≥75 years), the relative risk of all-cause and cause-specific mortality associated with most risk factors was higher in younger than older people, after mutually adjusting for the eight risk factors and other potential confounders including sex, diabetes duration, lipid profile, and medication use. The eight risk factors explained a larger proportion of mortality events in the youngest (PAF: 51.6%, 95% confidence interval [CI] [39.1%, 64.0%], p < 0.001) than the oldest (PAF: 35.3%, 95% CI [27.2%, 43.4%], p < 0.001) age group. Suboptimal blood pressure (PAF: 16.9%, 95% CI [14.7%, 19.1%], p < 0.001) was the leading attributable risk factor for all-cause mortality in the youngest age group, while CKD (PAF: 15.2%, 95% CI [14.0%, 16.4%], p < 0.001) and CVD (PAF: 9.2%, 95% CI [8.3%, 10.1%], p < 0.001) were the leading attributable risk factors in the oldest age group. The analysis was restricted to Chinese, which might affect the generalisability to the global population with differences in risk profiles. Furthermore, PAFs were estimated under the assumption of a causal relationship between risk factors and mortality. However, reliable causality was difficult to establish in the observational study.
      Conclusions: Major comorbidities and modifiable risk factors were associated with a greater relative risk for mortality in younger than older people with type 2 diabetes and their associations with population mortality burden varied substantially by age. These findings highlight the importance of early control of blood pressure, which could reduce premature mortality in young people with type 2 diabetes and prevent the onset of later CKD and related mortality at older ages.
      Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: R. C.W. M. is a Editorial Board member of Plos Medicine.
      (Copyright: © 2023 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Diabetologia. 2022 Jan;65(1):3-13. (PMID: 34837505)
      Lancet Glob Health. 2018 Jun;6(6):e641-e649. (PMID: 29773120)
      Lancet Healthy Longev. 2021 Jun;2(6):e340-e351. (PMID: 35211689)
      Diabetologia. 2020 Apr;63(4):757-766. (PMID: 31942668)
      Nat Rev Endocrinol. 2020 Jun;16(6):321-331. (PMID: 32203408)
      N Engl J Med. 1996 Jan 4;334(1):13-8. (PMID: 7494564)
      Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84. (PMID: 33298417)
      Lancet. 2002 Dec 14;360(9349):1903-13. (PMID: 12493255)
      Diabetes Obes Metab. 2020 Jan;22(1):3-5. (PMID: 31486276)
      Diabetes Res Clin Pract. 2022 Mar;185:109785. (PMID: 35189261)
      BMJ. 2017 Nov 14;359:j4849. (PMID: 29138133)
      Lancet. 2008 Jan 12;371(9607):117-25. (PMID: 18191683)
      N Engl J Med. 2011 Mar 3;364(9):818-28. (PMID: 21366473)
      JAMA. 2013 Jan 2;309(1):71-82. (PMID: 23280227)
      PLoS Med. 2020 Feb 20;17(2):e1003052. (PMID: 32078650)
      Lancet Diabetes Endocrinol. 2014 Dec;2(12):935-43. (PMID: 25081582)
      Diabetologia. 2020 Sep;63(9):1718-1735. (PMID: 32632526)
      Int J Epidemiol. 2022 May 9;51(2):e9-e17. (PMID: 34904159)
      JAMA. 2021 Aug 24;326(8):717-727. (PMID: 34427600)
      JAMA Netw Open. 2022 Mar 1;5(3):e223862. (PMID: 35333363)
      N Engl J Med. 2021 Jun 10;384(23):2219-2228. (PMID: 34107181)
      Eur J Epidemiol. 2016 Jun;31(6):575-82. (PMID: 26992709)
      N Engl J Med. 2011 Feb 24;364(8):719-29. (PMID: 21345101)
      JAMA. 2014 Feb 5;311(5):490-7. (PMID: 24496536)
      Diabetes Care. 2017 Jul;40(7):928-935. (PMID: 28490423)
      Diabetes Care. 2021 Jan;44(Suppl 1):S125-S150. (PMID: 33298421)
      Circulation. 1992 Sep;86(3):1046-60. (PMID: 1355411)
      Diabetes Care. 2009 Jun;32(6):977-82. (PMID: 19460913)
      Cardiovasc Diabetol. 2020 May 12;19(1):60. (PMID: 32398003)
      Hypertension. 2021 Jun;77(6):e58-e67. (PMID: 33910363)
      N Engl J Med. 2013 Apr 25;368(17):1613-24. (PMID: 23614587)
      Stat Med. 2010 Mar 30;29(7-8):860-74. (PMID: 20213711)
      JAMA. 2009 May 27;301(20):2129-40. (PMID: 19470990)
      N Engl J Med. 2014 Apr 17;370(16):1514-23. (PMID: 24738668)
      Diabetologia. 2006 Dec;49(12):2878-81. (PMID: 17031611)
      BMJ. 2020 Dec 8;371:m4266. (PMID: 33293274)
      N Engl J Med. 2008 Feb 7;358(6):580-91. (PMID: 18256393)
      N Engl J Med. 2018 Aug 16;379(7):633-644. (PMID: 30110583)
      N Engl J Med. 2008 Oct 9;359(15):1577-89. (PMID: 18784090)
      Lancet. 2021 Dec 19;396(10267):2019-2082. (PMID: 33189186)
      Diabetes Care. 2018 Mar;41(3):485-493. (PMID: 29298801)
      Biomed Environ Sci. 2004;17 Suppl:1-36. (PMID: 15807475)
    • الموضوع:
      Date Created: 20230130 Date Completed: 20230215 Latest Revision: 20230224
    • الموضوع:
      20240829
    • الرقم المعرف:
      PMC9925230
    • الرقم المعرف:
      10.1371/journal.pmed.1004173
    • الرقم المعرف:
      36716342